Catherine Sibyl (Magid) Diefenbach MD

PubMed

• A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
  Matthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, Catherine S Diefenbach, Daniel N Egan
  Blood Advances. 2025-02-25
• 3 citations
  Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial.
  Armin Ghobadi, Veronika Bachanova, Krish Patel, Jae H Park, Ian Flinn
  Lancet. 2025-01-11
• 1 citations
  The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era.
  Gaurav Varma, Catherine Diefenbach
  Seminars in Hematology. 2024-08-01

Journal Articles

• Ipilimumab, Nivolumab, and Brentuximab Vedotin Combination Therapies in Patients with Relapsed or Refractory Hodgkin Lymphoma: Phase 1 Results of an Open-Label, Multic...  
  Catherine (Magid) Diefenbach, MD, The Lancet Haematology
• CART19 in Hodgkin Lymphoma: Are We Driving the Right Model?  
  Catherine (Magid) Diefenbach, MD, Blood

Abstracts/Posters

• Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0407
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicit... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a p... 
  2019 ASCO Annual Meeting - 6/1/2019
• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Beyond Transplant: Novel Therapies in Relapsed Hodgkin Lymphoma 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
• Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all